ilaprazole has been researched along with Infections, Helicobacter in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, FH; Chen, C; Chen, RX; Chen, SJ; Huang, SM; Li, D; Zeng, F; Zhang, DY; Zhang, XD | 1 |
| Jung, SH; Kim, SH; Kim, SM; Lee, DS; Lee, SW; Moon, SJ; Song, KH; Sung, JK | 1 |
| Jin, Y; Pan, J; Wang, Q; Yao, D; Yue, M; Zhang, G; Zhang, S | 1 |
| Chen, MZ; Cong, YY; Huang, XP; Huang, YY; Liao, XM; Nong, GH; Wei, JQ; Wu, BH | 1 |
| Hu, H; Hu, P; Jiang, J; Lang, L; Ou, N; Shi, R; Wang, H | 1 |
| Chen, Y; Cheng, H; Cui, MH; Gao, HJ; Gao, W; Hu, FL; Lü, NH; Sheng, JQ; Xie, Y; Xu, JM; Yang, GB; Yang, L; Zhang, GX; Zhang, L; Zhang, LX; Zhang, ZY | 1 |
5 trial(s) available for ilaprazole and Infections, Helicobacter
| Article | Year |
|---|---|
Ilaprazole-amoxicillin dual therapy at high dose as a first-line treatment for helicobacter pylori infection in Hainan: a single-center, open-label, noninferiority, randomized controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Bismuth; Furazolidone; Helicobacter Infections; Helicobacter pylori; Humans | 2023 |
The prolongation effect of ilaprazole-based standard triple therapy for Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Prospective Studies | 2020 |
Comparison of efficacy and safety of ilaprazole and esomeprazole both in initial treatment regimen and retreatment regimen of Helicobacter pylori infection in chronic gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Chronic Disease; Drug Therapy, Combination; Esomeprazole; Female; Furazolidone; Gastritis; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Minocycline; Prospective Studies; Proton Pump Inhibitors; Retreatment; Treatment Failure; Treatment Outcome | 2019 |
Modified sequential therapy vs quadruple therapy as initial therapy in patients with Helicobacter infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; China; Chronic Disease; Clavulanic Acid; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastritis; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Middle Aged; Organometallic Compounds; Prospective Studies; Proton Pump Inhibitors; Time Factors; Treatment Outcome | 2015 |
[Ilaprazole based bismuth-containing quadruple regimen for the first-line treatment of Helicobacter pylori infection: a multicenter, randomized, controlled clinical study].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; China; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Male; Middle Aged; Omeprazole; Young Adult | 2012 |
1 other study(ies) available for ilaprazole and Infections, Helicobacter
| Article | Year |
|---|---|
Pharmacokinetics, Pharmacodynamics and Safety of Multiple-Infusion Ilaprazole in Healthy Chinese Subjects.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Asian People; Dose-Response Relationship, Drug; Female; Gastric Acidity Determination; Half-Life; Healthy Volunteers; Helicobacter Infections; Helicobacter pylori; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Male; Proton Pump Inhibitors; Stomach; Young Adult | 2016 |